Intelligent Medical Objects And Multiple Myeloma Research Foundation Partner To Enhance Data For Clinical Research

New partnership will enhance data quality to accelerate and improve clinical research

Intelligent Medical Objects (IMO) a healthcare data quality and enablement company and market leader in medical terminology solutions, and the Multiple Myeloma Research Foundation (MMRF), a leading cancer nonprofit organization dedicated to accelerating a cure for multiple myeloma, today announced a partnership to further improve the utility of the clinical data from its MMRF CureCloud and CoMMpass clinical trials.

Recommended AI News: 3i Infotech Charters a New Growth Path Through a Digital & Cloud-First Focus

The partnership will expand data utility of the clinical data generated by the landmark CureCloud and CoMMpass research programs that are used by the MMRF’s partners to drive precision treatments for myeloma patients. The added capabilities provided by IMO’s data normalization services will enhance the utility of the MMRF’s data for use cases such as patient identification for clinical trials, cohort selection for health outcomes research, and the enhanced ability to provide analytic precision to the MMRF’s real-world data sources.

“We are looking forward to partnering with IMO to streamline data analysis,” said Steven Labkoff, MD, MMRF’s Chief Data Officer. “As data leaves the electronic health records (EHRs) crucial metadata elements are often lost when EHRs create human-readable records. That metadata (ICD10, LOINC, RxNorm and other codes) is needed for secondary analysis and cohort creation. Without this information, it becomes a lot more complicated to analyze the data donated by our patients for analysis. By utilizing IMO technology, we will be able to re-introduce this data which in turn will help us to generate insights, and more importantly, help our researchers to more easily utilize our data in an effort to find c****.“

Through the CureCloud and CoMMpass research programs, the MMRF has generated some of the richest oncology data sets to drive new precision treatments and a cure for each and every myeloma patient. Recognizing an opportunity to gain more impactful insights from that data, MMRF partnered with IMO to leverage its technology, IMO Precision Normalize, a product that standardizes inconsistent diagnosis, procedure, medication, and lab data from diverse systems into common, clinically validated terminology.

Recommended AI News: Teledyne e2v Announces Low-Cost, High-Performance Quad Linear CMOS Sensor Family

“Any organization that’s in the business of collecting and analyzing clinical data needs to maximize the quality of that data, and the quality of that data depends on the ability to easily and quickly normalize it to precise and understandable standards,” said Dale Sanders, Chief Strategy Officer, IMO. “We are excited and grateful to partner with the MMRF to improve oncology patient care and treatment, as well as data quality for MMRF’s partners.”

Currently, as healthcare data moves out of the EHR and is aggregated for analytics, it can be inconsistent, incomplete, and inaccurate. Decision-making may be compromised, which may put patient safety and outcomes at risk. Used by over 500,000 physicians during point of care documentation, IMO clinical terminology forms the foundation of IMO Precision Normalize, helping IT leaders and data stewards address the challenges that come with managing and leveraging data derived from multiple health information systems and sources.

Recommended AI News: Frost & Sullivan Outlines Five Key Growth Opportunities In The Middle East ICT Market